Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) - XML Representation

Raw xml | Download


<ArtifactAssessment xmlns="http://hl7.org/fhir">
  <id value="179693"/>
  <meta>
    <versionId value="7"/>
    <lastUpdated value="2024-12-12T13:06:16.440Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/certainty-of-evidence"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ArtifactAssessment 179693</b></p><a name="179693"> </a><a name="hc179693"> </a><a name="179693-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 7; Last updated: 2024-12-12 13:06:16+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-certainty-of-evidence.html">CertaintyOfEvidence</a></p></div><p><b>Artifact URL</b>: <a href="https://fevir.net/resources/ArtifactAssessment/179693">https://fevir.net/resources/ArtifactAssessment/179693</a></p><p><b>Artifact Description</b>: </p><div><p>This example of a CertaintyOfEvidence Profile shows a recursive pattern of component elements with type/classifier paired values for different aspects of rating the certainty of evidence.</p>
</div><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/179693</p><p><b>title</b>: Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)</p><p><b>artifact</b>: <a href="Evidence-55.html">14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)</a></p><blockquote><p><b>content</b></p><p><b>summary</b>: </p><div><p>Low certainty due to inconsistency and risk of bias</p>
</div><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/certainty-type Overall}">Overall certainty</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/certainty-rating low}">Low quality</span></p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/certainty-type PublicationBias}">Publication bias</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/certainty-rating no-concern}">no serious concern</span></p></blockquote><blockquote><p><b>component</b></p><p><b>summary</b>: </p><div><p>There is a high degree of heterogeneity (I-squared = 73%). There is also inconsistency in findings between the fixed-effect and random-effects statistical models.</p>
</div><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/certainty-type Inconsistency}">Inconsistency</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/certainty-rating serious-concern}">serious concern</span></p></blockquote><blockquote><p><b>component</b></p><p><b>summary</b>: </p><div><p>Although the random-effects analysis finds an estimate without statistical significance, this imprecision is explained by the inconsistency (heterogeneity) and thus not further downrated in certainty assessment.</p>
</div><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/certainty-type Imprecision}">Imprecision</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/certainty-rating no-concern}">no serious concern</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/certainty-type Indirectness}">Indirectness</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/certainty-rating no-concern}">no serious concern</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/certainty-type RiskOfBias}">Risk of bias</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/certainty-rating serious-concern}">serious concern</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Summary</b></td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><div><p>No blinding (no placebo control) in the largest trial</p>
</div></td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/181513 SEVCO:00035}">Lack of blinding</span></td><td><span title="Codes:{http://hl7.org/fhir/certainty-rating present}">present</span></td></tr></table></blockquote></blockquote></div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-url">
    <valueUri value="https://fevir.net/resources/ArtifactAssessment/179693"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-description">
    <valueMarkdown
                   value="This example of a CertaintyOfEvidence Profile shows a recursive pattern of component elements with type/classifier paired values for different aspects of rating the certainty of evidence."/>
  </extension>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="urn:ietf:rfc:3986"/>
    <value value="https://fevir.net/FOI/179693"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <title
         value="Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)"/>
  <artifactReference>🔗 
    <reference value="Evidence/55"/>
    <type value="Evidence"/>
    <display
             value="14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)"/>
  </artifactReference>
  <content>
    <summary value="Low certainty due to inconsistency and risk of bias"/>
    <type>
      <coding>
        <system value="http://hl7.org/fhir/certainty-type"/>
        <code value="Overall"/>
        <display value="Overall certainty"/>
      </coding>
    </type>
    <classifier>
      <coding>
        <system value="http://hl7.org/fhir/certainty-rating"/>
        <code value="low"/>
        <display value="Low quality"/>
      </coding>
    </classifier>
    <component>
      <type>
        <coding>
          <system value="http://hl7.org/fhir/certainty-type"/>
          <code value="PublicationBias"/>
          <display value="Publication bias"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/certainty-rating"/>
          <code value="no-concern"/>
          <display value="no serious concern"/>
        </coding>
      </classifier>
    </component>
    <component>
      <summary
               value="There is a high degree of heterogeneity (I-squared = 73%). There is also inconsistency in findings between the fixed-effect and random-effects statistical models."/>
      <type>
        <coding>
          <system value="http://hl7.org/fhir/certainty-type"/>
          <code value="Inconsistency"/>
          <display value="Inconsistency"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/certainty-rating"/>
          <code value="serious-concern"/>
          <display value="serious concern"/>
        </coding>
      </classifier>
    </component>
    <component>
      <summary
               value="Although the random-effects analysis finds an estimate without statistical significance, this imprecision is explained by the inconsistency (heterogeneity) and thus not further downrated in certainty assessment."/>
      <type>
        <coding>
          <system value="http://hl7.org/fhir/certainty-type"/>
          <code value="Imprecision"/>
          <display value="Imprecision"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/certainty-rating"/>
          <code value="no-concern"/>
          <display value="no serious concern"/>
        </coding>
      </classifier>
    </component>
    <component>
      <type>
        <coding>
          <system value="http://hl7.org/fhir/certainty-type"/>
          <code value="Indirectness"/>
          <display value="Indirectness"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/certainty-rating"/>
          <code value="no-concern"/>
          <display value="no serious concern"/>
        </coding>
      </classifier>
    </component>
    <component>
      <type>
        <coding>
          <system value="http://hl7.org/fhir/certainty-type"/>
          <code value="RiskOfBias"/>
          <display value="Risk of bias"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/certainty-rating"/>
          <code value="serious-concern"/>
          <display value="serious concern"/>
        </coding>
      </classifier>
      <component>
        <summary
                 value="No blinding (no placebo control) in the largest trial"/>
        <type>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/181513"/>
            <code value="SEVCO:00035"/>
            <display value="Inadequate blinding of participants"/>
          </coding>
          <text value="Lack of blinding"/>
        </type>
        <classifier>
          <coding>
            <system value="http://hl7.org/fhir/certainty-rating"/>
            <code value="present"/>
            <display value="present"/>
          </coding>
        </classifier>
      </component>
    </component>
  </content>
</ArtifactAssessment>